Medtronic, Entering a Turbo-Charged Growth Phase

Recently, according to foreign media reports, Medtronic delivered a Q1 FY2027 financial performance far exceeding market expectations. On the same day, the company announced two strategic investments totaling $780 million. Image source: Latest Medical Device News on MassDevice With both exceptional financial results and major investments announced simultaneously, where is Medtronic allocating its newly earned capital? First, let’s examine Medtronic’s Q1 FY2027 results: For the quarter ended July 31, 2026, Medtronic reported revenue of $9.756 billion, representing a 13.7% year-on-year increase; GAAP net income reached $1.47 billion, surging 41.4% year-on-year. By business segment, all of Medtronic’s major business units achieved double-digit revenue growth. Cardiovascular revenue totaled $3.927 billion, up 19.5% year-on-year—accounting for 40% of total revenue. Notably, Cardiac Ablation Solutions (CAS), which includes pulsed field ablation (PFA) products, stood out with an 88% year-on-year growth—surging 139% in the U.S. market alone. CAS has demonstrated robust momentum in recent years, with next-generation PFA platforms—including the Affera 3D mapping system and the Sphere-9 dual-energy catheter—rapidly scaling up. Neuroscience revenue amounted to $2.678 billion, up 10.3%; Medical Surgical revenue reached $2.279 billion, up 10.0%. The remainder of revenue came from Medtronic’s stake in its diabetes business (now the independent public company MiniMed), generating $843 million in revenue—a 16.9% year-on-year increase. This business is expected to complete its spin-off by the end of the current fiscal year. Based on this outstanding Q1 performance, Medtronic raised its full-year organic revenue growth guidance from the prior range of 6.75%–7.25% to 7.25%–7.75%.

Medtronic’s FY2025 Q2 Earnings Show Strong Momentum: Innovation Drives Growth—Hugo Is Coming!

On November 19, Medtronic released its Q2 FY2025 financial results, demonstrating robust growth across multiple innovative business areas. The company’s CEO stated that he remains highly confident in continued growth drivers including transcatheter aortic valve replacement (TAVR), pulsed field ablation (PFA), neuromodulation, diabetes care, and renal denervation. He specifically highlighted that Medtronic plans to submit its Hugo robotic-assisted surgery system for FDA clearance in early 2025. In 2025, the da Vinci surgical robot will face its strongest-ever competitor—ending da Vinci’s era of market dominance. Undoubtedly, the ‘Hugo vs. da Vinci’ rivalry is about to begin, ushering in a new era for surgical robotics. ▍FY2025 Q2 Exceeds Expectations; Full-Year Guidance Raised Recently, Medtronic released its second-quarter (Q2) financial results for fiscal year 2025 (FY2025), covering the period ended October 2024. The strong performance prompted the company to raise the lower end of its full-year sales and adjusted EPS guidance. From a revenue perspective, Medtronic’s Q2 FY2025 report showed profits nearing $1.3 billion, earnings per share (EPS) of $0.99, and sales of $8.4 billion—an increase of 5.2% year-on-year, with organic growth of 5.0%. This result surpassed Wall Street’s consensus estimate of $8.27 billion. Medtronic raised its revenue growth guidance from the previous range of 4.5%–5.0% to 4.75%–5.0%. Its adjusted EPS guidance was updated from $5.42–$5.50 to $5.44–$5.50. Regarding stock price, although Medtronic’s shares fell over 1% at market open on the 19th—trading at $85.91 per share—the company’s financial performance still garnered market recognition. GAAP EPS stood at $0.99, while non-GAAP EPS was $1.26. All business segments performed strongly: ・Cardiovascular business grew 6.1% to $3.102 billion; ・Neuroscience business grew 7.1% to $2.451 billion; ・Medical Surgical business grew 1.2% to $2.128 billion; ・Diabetes business grew 12.4% to $686 million. Especially within cardiovascular, the arrhythmia and heart failure divisions achieved mid-to-high single-digit growth. The company emphasized growth in defibrillation solutions and cardiac pacing therapies, while cardiac ablation performance remained flat. Growth from the PulseSelect pulsed field ablation system offset declines in cryoablation. According to Geoff Martha, Medtronic’s Chairman and CEO, supply constraints caused by third-party component suppliers had previously limited PulseSelect system availability, hampering broader ablation business expansion. That supplier has now resumed normal operations, and increased production capacity is anticipated. In neuroscience, the cranial and spinal technologies division posted above-market performance, driven by continued adoption of the AiBLE spinal implant ecosystem. The neuromodulation division also delivered above-market results, fueled by the ongoing rollout of the Percept RC deep brain stimulation (DBS) system. Within Medical Surgical, the acute care and monitoring division achieved low single-digit growth, while the surgical and endoscopy division remained stable.

Balchem signals double-digit growth potential with new $36M microencapsulation facility and strong Q2 2025 results

Jun 23, 2026

Balchem invests $36M in Maryland microencapsulation facility for early 2026 Human Nutrition & Health operations. Q2 2025 results showed sales up 9% to $265M and net earnings rising 12%.

MSN

2026-03-22

BCPC SEC Filings - Balchem Corp 10-K, 10-Q, 8-K Forms

2026-03-27

Balchem Reports €0.0 Million NonCurrent Deferred Revenue as of December 2025

2026-04-09

Balchem Corp. Stock Valuation Revised Amid Competitive FMCG Landscape

2026-04-11

Balchem Reports $581 Million Gross Property, Plant and Equipment as of December 2025

2026-04-16

Zinc Methionine Chelates Market Forecast Report 2025-2033 Featuring Alltech, Balchem, Titan Biotech, UNO VETCHEM, Zinpro, Chaitanya Biologicals, Chengdu Chelation Biology, JH, Novus, Priya